Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
12:00pm, Friday, 05'th Jul 2024
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. (“PTC” or
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
04:54pm, Tuesday, 02'nd Jul 2024
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to co
PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
09:01am, Monday, 01'st Jul 2024
PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
06:00am, Friday, 28'th Jun 2024
- PTC to submit a request for re-examination - WARREN, N.J. , June 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the CHMP has issued a negative opinion on the re
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
05:45am, Monday, 24'th Jun 2024
PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more st
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 21'st Jun 2024
WARREN, N.J. , June 21, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 17, 2024, the company approved non-statutory stock options to purchase an aggregate of 1
- FDA lifts PTC518 partial clinical hold based on PIVOT-HD data - - Conference call and webcast to be held June 20 th at 8:00 am EDT - WARREN, N.J. , June 20, 2024 /PRNewswire/ -- PTC Therapeutics, I
PTC Therapeutics to Participate at Upcoming Investor Conference
08:00am, Wednesday, 29'th May 2024
WARREN, N.J. , May 29, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference: William Blair's 44th An
PTC Therapeutics Announces Validation of Sepiapterin European MAA
08:30am, Tuesday, 28'th May 2024
- Review of European marketing application for PKU now initiated - WARREN, N.J. , May 28, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the sepiapterin MAA for PKU ha
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
01:30pm, Tuesday, 21'st May 2024
PTC Therapeutics (PTCT) gains 21% on May 20 after the EC decided against adopting the negative CHMP opinion of January 2024 on the annual renewal of the conditional approval of Translarna.
PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'
04:05pm, Monday, 20'th May 2024
PTC stock hit a nine-month high Monday after the European Commission decided against pulling its drug, Translarna, from the market. Translarna has a conditional approval in Europe to treat patients wi
PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
07:00am, Monday, 20'th May 2024
- European Commission decides against adoption of negative opinion - - Translarna authorization remains active in Europe - - 2024 revenue guidance paused - WARREN, N.J. , May 20, 2024 /PRNewswire/ --
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
07:30am, Tuesday, 14'th May 2024
- PDUFA target action date of November 13, 2024 - WARREN, N.J. , May 14, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics L
PTC Therapeutics to Participate at Upcoming Investor Conferences
08:00am, Thursday, 02'nd May 2024
WARREN, N.J. , May 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: RBC Capital Markets 2024
